DOW JONES23,719.37+285.80 1.22%
S&P 5002,789.82+39.84 1.45%
NASDAQ8,153.58+62.67 0.77%

Wedbush Maintains Outperform on Corvus Pharmaceuticals, Lowers Price Target to $8

Wedbush maintains Corvus Pharmaceuticals (NASDAQ:CRVS) with a Outperform and lowers the price target from $11 to $8.

Benzinga · 03/13/2020 12:47

Wedbush maintains Corvus Pharmaceuticals (NASDAQ:CRVS) with a Outperform and lowers the price target from $11 to $8.